Share via Email

Chr. Hansen A/S reported Q4 revenue of $363 million with earnings before interest and taxes (EBIT) of $125 million.  For the quarter, growth in revenue attained seven percent with the Health and Nutrition segment contributing 18 percent to EBIT.  The Food Cultures and Enzyme segment contributed five percent to organic growth.

For fiscal 2020, revenue attained $1.403 billion with an EBIT of $420 million for the entire year, revenue increased by five percent with the Health and Nutrition segment contributing nine percent.

In providing guidance for FY2021, the company anticipates revenue growth of between five and eight percent and an EBIT margin of 27 to 28 percent.

In commenting on results, CEO Mauricio Graber stated, "2019/2020 was a defining and extremely eventful year for Chr. Hansen.  We launched our new 2025 strategy to become a focused bioscience company and to grow a better world naturally".  He added "everyone has had to manage through a pandemic which has imposed unique challenges"